(Q43106099)

14 November 2017

0 references

Ezetimibe and recent clinical trials: a look on the bright side (English)

1 reference

14 November 2017

Mohamed H Ahmed

1

1 reference

14 November 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

Expert Opinion on Drug Safety

14 November 2017

published in

1 reference

14 November 2017

volume

9

1 reference

14 November 2017

issue

4

1 reference

14 November 2017

page(s)

511-514

1 reference

14 November 2017

cites work

Ezetimibe/simvastatin

1 reference

https://api.crossref.org/works/10.1517%2F14740331003702376

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003702376

Extended-release niacin or ezetimibe and carotid intima-media thickness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003702376

Simvastatin with or without ezetimibe in familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003702376

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003702376

Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003702376

Ezetimibe ameliorates cholecystosteatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003702376

Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003702376

Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003702376

The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003702376

The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003702376

Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003702376

Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003702376

Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003702376

A retrospective analysis of ezetimibe treatment in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003702376

Ezetimibe, and the combination of ezetimibe/simvastatin, and risk of cancer: A post-marketing analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003702376

Analyses of cancer data from three ezetimibe trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740331003702376

10.1517/14740331003702376

21 January 2018

Identifiers

DOI

1 reference

14 November 2017

1 reference